
Sign up to save your podcasts
Or
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
4.5
232232 ratings
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
43,851 Listeners
30,850 Listeners
32,184 Listeners
26,180 Listeners
59,118 Listeners
2,171 Listeners
4,114 Listeners
9,531 Listeners
9,582 Listeners
570 Listeners
14,525 Listeners
5,094 Listeners
404 Listeners
71 Listeners
1,829 Listeners
3,719 Listeners
2,093 Listeners
80 Listeners
380 Listeners
2,144 Listeners
234 Listeners
1,210 Listeners
232 Listeners
433 Listeners
147 Listeners
374 Listeners
332 Listeners
33 Listeners
95 Listeners
78 Listeners
249 Listeners
242 Listeners